Management of vascular access after TAVR: Let's keep it simple.
Bleeding and vascular complications are major causes of morbidity and mortality after transfemoral TAVR. Compared with standard approaches to hemostasis, the catheter balloon occlusion technique CBOT) resulted in significant reduction in major bleeding and vascular complications (18.6% vs. 5.5%, P = 0.042). Femoral crossover could not be achieved in 3.6%, and CBOT led to vessel dissection in 7.2%, major or life-threatening bleeding in 5.5%, need for transfusion > 2 units in 10.9%, and minor bleeding or hematoma in 21.8% of patients.